A Study Comparing Sevoflurane and Propofol in Patients Undergoing Endobronchial Ultrasound Guided Needle Aspiration

NCT07338578 | Completed

• 1 other identifier: SBU-HAMIDIYE-23-57
• Study Type: observational
• Target: 102
• Locations: 1 country
• Sites: 1

Brief Summary

Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive procedure used to obtain samples from mediastinal and hilar lymph nodes or lung parenchymal lesions for diagnostic and staging purposes. The success and safety of the procedure, including diagnostic yield, complication rates, and bronchoscopist comfort, depend largely on the choice of anesthesia technique. General anesthesia is frequently preferred because it provides a stable airway, adequate ventilation, and improved procedural conditions. Patient-related factors such as medical status, history, procedure duration, and number of needle passes may influence hemodynamic stability and tolerance, making anesthesiologist involvement essential. Previous studies comparing intravenous and inhalational anesthesia in various surgical and bronchoscopic procedures have evaluated their effects on hemodynamics, complications, recovery time, visibility of the surgical field, and postoperative outcomes. However, there is limited evidence directly comparing propofol-based total intravenous anesthesia and sevoflurane-based inhalational anesthesia specifically for EBUS-TBNA. This study aims to compare the effects of propofol and sevoflurane anesthesia on perioperative hemodynamic parameters, respiratory stability, and procedure-related complications in patients undergoing EBUS-TBNA. In addition, the study assesses bronchoscopist satisfaction with each anesthetic technique, including procedural comfort and working conditions. The findings are expected to contribute to optimizing anesthetic management for EBUS-TBNA, improving patient safety, and enhancing procedural quality.

Conditions

Hemodynamic Stability; Pulmonary Diseases or Conditions; Complication of Anesthesia

Keywords

EBUS; Propofol; Sevoflurane; Outpatient Anesthesia; General Anesthesia

Outcome Measures

Primary Outcomes (4)

• Change in Systolic Blood Pressure During EBUS-TBNA

  Systolic blood pressure (mmHg) will be measured at baseline (pre-induction), immediately after induction, during the procedure at 5-minute intervals, at the end of the procedure, and upon arrival in the recovery room. Values will be compared between the propofol and sevoflurane groups.

  Periprocedural period (from anesthesia induction to 60 minutes after procedure completion)

• Change in Diastolic Blood Pressure During EBUS-TBNA

  Diastolic blood pressure (mmHg) will be measured at baseline (pre-induction), immediately after induction, during the procedure at 5-minute intervals, at the end of the procedure, and upon arrival in the recovery room. Values will be compared between the propofol and sevoflurane groups.

  Periprocedural period (from anesthesia induction to 60 minutes after procedure completion)

• Change in Heart Rate During EBUS-TBNA

  Heart rate (beats per minute) will be recorded at baseline (pre-induction), immediately after induction, during the procedure at 5-minute intervals, at the end of the procedure, and upon arrival in the recovery room. Values will be compared between the propofol and sevoflurane groups.

  Periprocedural period (from anesthesia induction to 60 minutes after procedure completion)

• Bronchoscopist Satisfaction Score During EBUS-TBNA

  Bronchoscopist satisfaction will be assessed using a standardized 5-point Likert scale, where higher scores indicate greater satisfaction.

  Immediately after completion of the procedure.

Secondary Outcomes (1)

• Procedure-Related Complications

  During the procedure and up to 1 hour postoperatively.

Study Arms (2)

Group 1: Propofol Group

Group 1: Patients who received total intravenous anesthesia (TIVA) with propofol during EBUS-TBNA.

Drug: propofol

Group 2: Sevoflurane Group

Patients who received inhalational anesthesia with sevoflurane during EBUS-TBNA.

Drug: Sevoflurane

Interventions

propofol DRUG

In group 1, anesthesia was induced intravenously and maintained using propofol to achieve an adequate depth of anesthesia and hemodynamic stability during EBUS- TBNA. The airway was managed with a size 4 laryngeal mask airway (LMA) allowing bronchoscope insertion and controlled ventilation. Standard monitoring included ECG, noninvasive blood pressure, pulse oximetry, and capnography.

Also known as: Diprivan

Group 1: Propofol Group

Sevoflurane DRUG

In group 2, following intravenous induction, anesthesia was maintained using sevoflurane in an oxygen-air mixture to ensure adequate depth of anesthesia and hemodynamic stability during EBUS-TBNA. Airway management was achieved using a size 4 laryngeal mask airway (LMA) to facilitate bronchoscope insertion and controlled ventilation. Standard monitoring included ECG, noninvasive blood pressure, pulse oximetry, and capnography.

Also known as: Sevorane

Group 2: Sevoflurane Group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The study population consisted of adult patients who underwent endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) under general anesthesia at a tertiary training and research hospital. All participants were scheduled for diagnostic bronchoscopy for evaluation of pulmonary or mediastinal lesions. Patients with American Society of Anesthesiologists (ASA) physical status I-III were included.

You may qualify if:

• Adults (\> 18 years) with an ASA physical status I-III who provided written informed consent were included.

You may not qualify if:

• ASA ≥ IV
• chronic cough or dyspnea
• preoperative desaturation (SpO₂ \< 90%)
• hypotension (MAP \< 60 mmHg),
• bradycardia (HR \< 60 bpm),
• hypersensitivity to anesthetics,
• any form of organ failure,
• laboratory abnormalities (electrolyte imbalance, anemia, polycythemia, thrombocytosis, leukopenia, or leukocytosis),
• perioperative hypo- or hyperthermia, dehydration, or overhydration.

Sponsors & Collaborators

• Saglik Bilimleri Universitesi: lead

Study Sites (1)

University of Health Sciences, Sultan 2. Abdulhamid Han Training and Research Hospital

Istanbul, Uskudar, 34668, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Lung Diseases

Interventions

Propofol; Sevoflurane

Condition Hierarchy (Ancestors)

Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Methyl Ethers; Ethers; Hydrocarbons, Fluorinated; Hydrocarbons, Halogenated

Study Officials

• Burcu Sari, MD

  University of Health Sciences, Sultan 2. Abdulhamid Han Training and Research Hospital

  PRINCIPAL INVESTIGATOR

• Tuna Erturk, MD

  University of Health Sciences, Sultan 2. Abdulhamid Han Training and Research Hospital

  STUDY CHAIR

• Suheyla Abitagaoglu, MD

  University of Health Sciences, Sultan 2. Abdulhamid Han Training and Research Hospital

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 17, 2025
• First Posted: January 14, 2026
• Study Start: September 1, 2023
• Primary Completion: March 4, 2024
• Study Completion: April 5, 2024
• Last Updated: January 14, 2026

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)